Belong.Life CAIHL draft report

Belong.Life: CAIHL reassessment

September 8, 2026. Published AI-assisted draft.

BelongAI Dave offers patient cancer questions, information, and document sharing. Its policy also permits commercial content and secondary use of depersonalized history. The posture is Mixed, with consumer and enterprise deployments assessed separately.

Scope and agency posture

BelongAI Dave cancer mentor and patient community. Enterprise private-label and clinical tools have different operators and require separate deployment descriptions.

Posture: Mixed.

Axis: 69/100, retained provisionally. No numerical recalibration was performed.

Sources and documented findings

• The current Dave page offers patient questions, treatment information, a proactive library and a digital binder with private sharing. Testimonials and medical-validation claims are vendor-selected evidence, not proof of reliable advice. https://belong.life/belong-ai-cancer-mentor-app/

• The privacy policy permits sponsored content and commercial partner disclosures, names LLM providers such as OpenAI, offers account editing/deletion, and allows depersonalized history to remain for improvement. https://belong.life/privacy-policy/

• The homepage markets private-label services to providers, pharmaceutical companies and payers as well as consumer mentors. https://belong.life/

Patient authority

Inference from the documented workflow: Patients can ask their own questions and choose document sharing in the described consumer workflow. Sponsor-content mechanisms create additional objectives, but actual steering of clinical recommendations was not established.

Critical capacity

Editorial assessment: Cancer information, community experience and a shareable binder can broaden patient questions. Per-answer citations, correction of mentor interpretations and moderation appeals were not verified.

Informed control

Editorial assessment: The seed's general positive label needs the documented commercial and secondary-use conditions. Account deletion is not a promise to remove every depersonalized derivative.

Assessment and limits

Replace the unqualified seed posture with Mixed, patient-directed questions with commercial-content and secondary-use conditions. This follows actual policy mechanisms rather than inferring misalignment from funding.

Confidence: Moderate for public product and policy claims, limited for actual patient experience.

Remaining uncertainty: Sponsor visibility, mentor source provenance, redirection and correction behavior remain unverified

Published documentation is evidence of stated conditions, not proof of actual implementation. Unknowns did not receive automatic negative points. Funding, sponsorship, and public code do not determine agency by themselves.

Review provenance

• Reviewer/model: OpenAI Codex / GPT-6.
• Method: Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
• Human review: Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
• Earlier review: 2026-06-12. Historical assessment. Earlier claims are not automatically reverified by this publication.